Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91


UA62784, a novel inhibitor of centromere protein E kinesin-like protein.

Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, Von Hoff DD.

Mol Cancer Ther. 2009 Jan;8(1):36-44. doi: 10.1158/1535-7163.MCT-08-0789.


High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells.

Sohn TA, Su GH, Ryu B, Yeo CJ, Kern SE.

Ann Surg. 2001 May;233(5):696-703.


MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer.

Hao J, Zhang S, Zhou Y, Hu X, Shao C.

FEBS Lett. 2011 Jan 3;585(1):207-13. doi: 10.1016/j.febslet.2010.11.039. Epub 2010 Nov 27.


Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.

Peng B, Fleming JB, Breslin T, Grau AM, Fojioka S, Abbruzzese JL, Evans DB, Ayers D, Wathen K, Wu T, Robertson KD, Chiao PJ.

Clin Cancer Res. 2002 Nov;8(11):3628-38.


Characterization of a membrane-active anti-tumor agent, UA8967.

Dorr RT, Samulitis BK, Wisner L, Han H, Zhao Y, Beroza P, Damodaran K, Igarashi S, Landowski TH, Von Hoff DD.

Invest New Drugs. 2013 Jun;31(3):576-86. doi: 10.1007/s10637-012-9901-z. Epub 2012 Nov 23.


MicroRNA 421 suppresses DPC4/Smad4 in pancreatic cancer.

Hao J, Zhang S, Zhou Y, Liu C, Hu X, Shao C.

Biochem Biophys Res Commun. 2011 Mar 25;406(4):552-7. doi: 10.1016/j.bbrc.2011.02.086. Epub 2011 Feb 23.


Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.

Wilentz RE, Su GH, Dai JL, Sparks AB, Argani P, Sohn TA, Yeo CJ, Kern SE, Hruban RH.

Am J Pathol. 2000 Jan;156(1):37-43.


Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle.

Chiao PJ, Hunt KK, Grau AM, Abramian A, Fleming J, Zhang W, Breslin T, Abbruzzese JL, Evans DB.

Ann N Y Acad Sci. 1999 Jun 30;880:31-7.


SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo.

Xia Y, Lei Q, Zhu Y, Ye T, Wang N, Li G, Shi X, Liu Y, Shao B, Yin T, Zhao L, Wu W, Song X, Xiong Y, Wei Y, Yu L.

Cancer Lett. 2014 Dec 28;355(2):297-309. doi: 10.1016/j.canlet.2014.09.042. Epub 2014 Oct 7.


Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.

Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S.

Ann Surg. 2013 Aug;258(2):336-46. doi: 10.1097/SLA.0b013e3182827a65.


Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer.

Shaw AY, Henderson MC, Flynn G, Samulitis B, Han H, Stratton SP, Chow HH, Hurley LH, Dorr RT.

J Pharmacol Exp Ther. 2009 Nov;331(2):636-47. doi: 10.1124/jpet.109.156406. Epub 2009 Aug 5.


Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells.

Chen WB, Lenschow W, Tiede K, Fischer JW, Kalthoff H, Ungefroren H.

J Biol Chem. 2002 Sep 27;277(39):36118-28. Epub 2002 Jul 24.


Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175.

Hayward RL, Schornagel QC, Tente R, Macpherson JS, Aird RE, Guichard S, Habtemariam A, Sadler P, Jodrell DI.

Cancer Chemother Pharmacol. 2005 Jun;55(6):577-83. Epub 2005 Feb 22.


Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity.

Cui Y, Brosnan JA, Blackford AL, Sur S, Hruban RH, Kinzler KW, Vogelstein B, Maitra A, Diaz LA Jr, Iacobuzio-Donahue CA, Eshleman JR.

Clin Cancer Res. 2012 Dec 1;18(23):6519-30. doi: 10.1158/1078-0432.CCR-12-0827. Epub 2012 Jul 2.


DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.

Biankin AV, Morey AL, Lee CS, Kench JG, Biankin SA, Hook HC, Head DR, Hugh TB, Sutherland RL, Henshall SM.

J Clin Oncol. 2002 Dec 1;20(23):4531-42.


Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.

Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, Liu M, Wang G, Lu Y, McEachern D, Bernard D, Bradford CR, Carey TE, Wang S.

Mol Cancer Ther. 2008 Jun;7(6):1533-42. doi: 10.1158/1535-7163.MCT-08-0140.


Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas.

Bartsch D, Barth P, Bastian D, Ramaswamy A, Gerdes B, Chaloupka B, Deiss Y, Simon B, Schudy A.

Cancer Lett. 1999 May 3;139(1):43-9.


Supplemental Content

Support Center